Cargando…
Influence of Enzyme-Inducing Antiepileptic Drugs on Trough Level of Imatinib in Glioblastoma Patients
BACKGROUND: Imatinib mesylate is used in combination with hydroxyurea (HU) in ongoing clinical phase II studies in recurrent glioblastoma multiforme (GBM). CYP3A4 enzyme-inducing antiepileptic drugs (EIAEDs) like carbamazepine, phenytoin, and oxcarbazepine - as well as non-EIAEDs like valproic acid,...
Autores principales: | Pursche, Stefan, Schleyer, Eberhard, von Bonin, Malte, Ehninger, Gerhard, Said, Samir Mustafa, Prondzinsky, Roland, Illmer, Thomas, Wang, Yanfeng, Hosius, Christian, Nikolova, Zariana, Bornhäuser, Martin, Dresemann, Gregor |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748699/ https://www.ncbi.nlm.nih.gov/pubmed/18781906 http://dx.doi.org/10.2174/157488408785747656 |
Ejemplares similares
-
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
por: Reardon, D A, et al.
Publicado: (2009) -
Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level
por: Wu, Xingye, et al.
Publicado: (2023) -
Association of the Trough, Peak/Trough Ratio of Imatinib, Pyridine–N-Oxide Imatinib and ABCG2 SNPs 34 G>A and SLCO1B3 334 T>G With Imatinib Response in Egyptian Chronic Myeloid Leukemia Patients
por: Omran, Mervat M., et al.
Publicado: (2020) -
Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a german multicenter trial
por: Schlemmer, M, et al.
Publicado: (2011) -
Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)